Q-omics provides the consensus-scored PAICSP2 profile across patient tissues and cancer cell-line models. PAICSP2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PAICSP2 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, PAICSP2 RNA expression shows 6,331 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, and STAD as cancer lineages where PAICSP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAICSP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAICSP2 survival associations across molecular data types. PAICSP2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAICSP2 RNA expression–survival associations across cancer types. High PAICSP2 expression shows unfavorable associations in KIRC, LIHC, TGCT, SKCM, COAD and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for PAICSP2 RNA expression.
This table summarizes PAICSP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for PAICSP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAICSP2 shows lower tumor expression in STAD. The STAD box plot shows higher PAICSP2 RNA expression in normal versus tumor tissue (log2 FC = −0.041, t-test p = .022).
This table shows molecular features associated with PAICSP2 in patient tissues and cancer cell lines. In patient samples, PAICSP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
